| In ZINC since | Heavy atoms | Benign functionality |
|---|---|---|
| October 21st, 2005 | 42 | No |
(-)-Etoposide;Etoposidum [INN-Latin];trans-Etoposide
33419-42-0; C01576; Etoposide; VP-16
33419-42-0; D00125; Etoposide (JP16/USP/INN); Vepesid (TN)
33419-42-0; Etoposide; Prestwick_211
4'-Demethyl-epipodophyllotoxin 9-[4,6-O-(R)-ethylidene-beta-D-glucopyranoside
4'-Demethylepipodophyllotoxin 9-(4,6-O-(R)-ethylidene-beta-D-glucopyranoside)
4'-Demethylepipodophyllotoxin 9-(4,6-O-ethylidene-beta-D-glucopyranoside)
4'-Demethylepipodophyllotoxin ethylidene-.beta.-D-glucoside
4'-O-Demethyl-1-O-(4,6-O-ethylidene-beta-D-glucopyranosyl)epipodophyllotoxin
4-Demethylepipodophyllotoxin beta-D-ethylideneglucoside
4-Demethylepipodophyllotoxin-.beta.-D-ethylideneglucoside
CPD000112002; Etoposide; SAM001246880
DEMETHY-EPIPODOPHYLLOTOXIN,ETHYLIDENE GLUCOSIDE,
Demethyl Epipodophyllotoxin Ethylidine Glucoside
Demethyl-epiodophyllotoxin ethylidene glucoside
Demethylepipodophyllotoxin-beta-D-ethylideneglucoside
Epipodophyllotoxin, 4'-demethyl-, 4,6-O-ethylidene-.beta.-D-glucopyranoside
Epipodophyllotoxin, 4'-demethyl-, 4,6-O-ethylidene-beta-D-glucopyranoside
Epipodophyllotoxin, 4'-demethyl-, 4,6-O-ethylidene-beta-D-glucopyranoside (8CI)
Epipodophyllotoxin, 4'-demethyl-, 9-(4,6-O-ethylidene-.beta.-D-glucopyranoside)
Epipodophyllotoxin, 4'-demethyl-, 9-(4,6-O-ethylidene-beta-D-glucopyranoside)
Epipodophyllotoxin-beta-D-ethyliden-glucoside, 4'-demethyl-
Eposin, Vepesid, VP-16, Toposar, Etoposide
Eposin; Etopophos; Lastet; Toposar; Vepesid
| Type pH range | xlogP | Des A‑Pol Apolar desolvation (kcal/mol) | Des Pol Polar desolvation (kcal/mol) | H Don H-bond donors | H Acc H-bond acceptors | Chg Net charge | tPSA (Ų) | MWT Molecular weight (g/mol) | RB Rotatable bonds | DL |
|---|---|---|---|---|---|---|---|---|---|---|
| Ref Reference (pH 7) | 0.70 | -7.49 | -18.52 | 3 | 13 | 0 | 160 | 588.562 | 5 | ↓ |
| Note Type | Comments | Provided By |
|---|---|---|
| ALOGPS_SOLUBILITY | 9.78e-01 g/l | DrugBank-approved |
| UniProt Database Links | AIFM2_MOUSE; ANM7_HUMAN; CP3A4_HUMAN; EI24_BOVIN; EI24_HUMAN; EI24_MOUSE; EI24_RAT; FA32A_HUMAN; FBX31_HUMAN; HIPK2_HUMAN; HNRPK_BOVIN; HNRPK_HUMAN; HNRPK_MACFA; HNRPK_MOUSE; HNRPK_PONAB; HNRPK_RABIT; HNRPK_RAT; ING2_HUMAN; NDK_YEAST; QORX_HUMAN; SQSTM_MO | ChEBI |
| Therapy | antineoplastic | SMDC MicroSource |
| biological_use | Antineoplastic agent | IBScreen Bioactives |
| mechanism | DNA topoisomerase II inhibitor | IBScreen Bioactives |
| PUBCHEM_PATENT_ID | EP0007597A1; EP0110955A1; EP0110955B1; EP0111058A1; EP0120907A1; EP0141057A1; EP0161915A2; EP0162701A2; EP0178624A2; EP0185740A1; EP0193287A2; EP0196269A2; EP0196618A1; EP0197342A1; EP0199063A2; EP0199917A2; EP0200961A2; EP0204982A2; EP0209609A1; EP021523 | IBM Patent Data |
| Patent Database Links | EP1110552; EP1243276; EP1295607; EP1428531; EP1438962; EP1457490; EP1493445; EP1498127; EP1514877; EP1531181; EP1537858; EP1537861; EP1538164; EP1543839; EP1552841; EP1574213; EP1574499; EP1579874; EP1579877; EP1580188; EP1584682; EP1598081; EP1611879; EP | ChEBI |
| PUBCHEM_SUBSTANCE_COMMENT | NCC_SAMPLE_SUPPLIER : Sigma Chemical Company; NCC_SUPPLIER_STRUCTURE_ID : E1383 | NIH Clinical Collection via PubChem |
| PUBCHEM_SUBSTANCE_COMMENT | SAMPLE_SUPPLIER: Sigma Chemical Company; SUPPLIER_STRUCTURE_ID: E1383 | NIH Clinical Collection via PubChem |
| Code | Description | Organism Class | Affinity (nM) | LE (kcal/mol/atom) | Type |
|---|---|---|---|---|---|
| CASP3-1-E | Caspase-3 (cluster #1 Of 2), Eukaryotic | Eukaryotes | 1000 | 0.20 | Binding ≤ 10μM |
| TOP2A-1-E | DNA Topoisomerase II Alpha (cluster #1 Of 2), Eukaryotic | Eukaryotes | 810 | 0.20 | Binding ≤ 10μM |
| TOP2B-1-E | DNA Topoisomerase II Beta (cluster #1 Of 2), Eukaryotic | Eukaryotes | 810 | 0.20 | Binding ≤ 10μM |
| TOP1-1-E | DNA Topoisomerase I (cluster #1 Of 1), Eukaryotic | Eukaryotes | 25 | 0.25 | Functional ≤ 10μM |
| TOP2A-1-E | DNA Topoisomerase II Alpha (cluster #1 Of 1), Eukaryotic | Eukaryotes | 25 | 0.25 | Functional ≤ 10μM |
| TOP2B-1-E | DNA Topoisomerase II Beta (cluster #1 Of 1), Eukaryotic | Eukaryotes | 25 | 0.25 | Functional ≤ 10μM |
| Z100733-1-O | CT26 (Colon Carcinoma Cells) (cluster #1 Of 1), Other | Other | 200 | 0.22 | Functional ≤ 10μM |
| Z100752-1-O | Renca (Renal Carcinoma Cells) (cluster #1 Of 1), Other | Other | 2900 | 0.18 | Functional ≤ 10μM |
| Z103203-1-O | A375 (cluster #1 Of 3), Other | Other | 3920 | 0.18 | Functional ≤ 10μM |
| Z103204-2-O | A427 (cluster #2 Of 4), Other | Other | 130 | 0.23 | Functional ≤ 10μM |
| Z103413-1-O | SW948 (cluster #1 Of 1), Other | Other | 1300 | 0.20 | Functional ≤ 10μM |
| Z50425-1-O | Plasmodium Falciparum (cluster #1 Of 22), Other | Other | 5012 | 0.18 | Functional ≤ 10μM |
| Z50587-5-O | Homo Sapiens (cluster #5 Of 9), Other | Other | 990 | 0.20 | Functional ≤ 10μM |
| Z80008-1-O | 5637 (Epithelial Bladder Carcinoma Cells) (cluster #1 Of 3), Other | Other | 530 | 0.21 | Functional ≤ 10μM |
| Z80025-1-O | ACHN (Renal Adenocarcinoma Cells) (cluster #1 Of 3), Other | Other | 2150 | 0.19 | Functional ≤ 10μM |
| Z80026-1-O | AGS (Gastric Adenocarcinoma Cells) (cluster #1 Of 2), Other | Other | 360 | 0.21 | Functional ≤ 10μM |
| Z80035-1-O | B16 (Melanoma Cells) (cluster #1 Of 7), Other | Other | 9000 | 0.17 | Functional ≤ 10μM |
| Z80064-1-O | CCRF-CEM (T-cell Leukemia) (cluster #1 Of 9), Other | Other | 2 | 0.29 | Functional ≤ 10μM |
| Z80064-1-O | CCRF-CEM (T-cell Leukemia) (cluster #1 Of 9), Other | Other | 1200 | 0.20 | Functional ≤ 10μM |
| Z80068-1-O | CCRF-SB (Lymphoblastic Leukemia Cells) (cluster #1 Of 5), Other | Other | 100 | 0.23 | Functional ≤ 10μM |
| Z80088-1-O | CHO (Ovarian Cells) (cluster #1 Of 4), Other | Other | 350 | 0.22 | Functional ≤ 10μM |
| Z80112-1-O | DAN-G (cluster #1 Of 2), Other | Other | 380 | 0.21 | Functional ≤ 10μM |
| Z80125-1-O | DU-145 (Prostate Carcinoma) (cluster #1 Of 9), Other | Other | 5160 | 0.18 | Functional ≤ 10μM |
| Z80156-2-O | HL-60 (Promyeloblast Leukemia Cells) (cluster #2 Of 12), Other | Other | 970 | 0.20 | Functional ≤ 10μM |
| Z80164-1-O | HT-1080 (Fibrosarcoma Cells) (cluster #1 Of 6), Other | Other | 750 | 0.20 | Functional ≤ 10μM |
| Z80166-1-O | HT-29 (Colon Adenocarcinoma Cells) (cluster #1 Of 12), Other | Other | 6600 | 0.17 | Functional ≤ 10μM |
| Z80179-1-O | J82 (Bladder Carcinoma Cells) (cluster #1 Of 1), Other | Other | 800 | 0.20 | Functional ≤ 10μM |
| Z80186-9-O | K562 (Erythroleukemia Cells) (cluster #9 Of 11), Other | Other | 522 | 0.21 | Functional ≤ 10μM |
| Z80188-1-O | KB 3-1 (Cervical Epithelial Carcinoma Cells) (cluster #1 Of 2), Other | Other | 567 | 0.21 | Functional ≤ 10μM |
| Z80193-2-O | L1210 (Lymphocytic Leukemia Cells) (cluster #2 Of 12), Other | Other | 834 | 0.20 | Functional ≤ 10μM |
| Z80211-1-O | LoVo (Colon Adenocarcinoma Cells) (cluster #1 Of 5), Other | Other | 2300 | 0.19 | Functional ≤ 10μM |
| Z80224-1-O | MCF7 (Breast Carcinoma Cells) (cluster #1 Of 14), Other | Other | 878 | 0.20 | Functional ≤ 10μM |
| Z80244-4-O | MDA-MB-468 (Breast Adenocarcinoma) (cluster #4 Of 7), Other | Other | 600 | 0.21 | Functional ≤ 10μM |
| Z80284-3-O | MOLT-3 (T-lymphoblastic Leukemia Cells) (cluster #3 Of 3), Other | Other | 65 | 0.24 | Functional ≤ 10μM |
| Z80285-1-O | MOLT-4 (Acute T-lymphoblastic Leukemia Cells) (cluster #1 Of 4), Other | Other | 0 | 0.00 | Functional ≤ 10μM |
| Z80288-1-O | MOVP-3 (cluster #1 Of 1), Other | Other | 7550 | 0.17 | Functional ≤ 10μM |
| Z80295-6-O | MT4 (Lymphocytes) (cluster #6 Of 8), Other | Other | 1250 | 0.20 | Functional ≤ 10μM |
| Z80322-2-O | NCI-H358 (Lung Carcinama Cells) (cluster #2 Of 2), Other | Other | 1500 | 0.19 | Functional ≤ 10μM |
| Z80362-1-O | P388 (Lymphoma Cells) (cluster #1 Of 8), Other | Other | 50 | 0.24 | Functional ≤ 10μM |
| Z80390-2-O | PC-3 (Prostate Carcinoma Cells) (cluster #2 Of 10), Other | Other | 7800 | 0.17 | Functional ≤ 10μM |
| Z80435-1-O | RT-112 (cluster #1 Of 1), Other | Other | 220 | 0.22 | Functional ≤ 10μM |
| Z80436-1-O | RT-4 (cluster #1 Of 1), Other | Other | 1330 | 0.20 | Functional ≤ 10μM |
| Z80473-1-O | SISO (cluster #1 Of 2), Other | Other | 150 | 0.23 | Functional ≤ 10μM |
| Z80475-1-O | SK-BR-3 (Breast Adenocarcinoma) (cluster #1 Of 3), Other | Other | 300 | 0.22 | Functional ≤ 10μM |
| Z80482-1-O | SK-MEL-2 (Melanoma Cells) (cluster #1 Of 4), Other | Other | 5720 | 0.17 | Functional ≤ 10μM |
| Z80485-1-O | SK-MEL-28 (Melanoma Cells) (cluster #1 Of 6), Other | Other | 850 | 0.20 | Functional ≤ 10μM |
| Z80490-3-O | SK-MES-1 (cluster #3 Of 4), Other | Other | 2500 | 0.19 | Functional ≤ 10μM |
| Z80491-2-O | SK-N-MC (Neuroepithelioma Cells) (cluster #2 Of 4), Other | Other | 275 | 0.22 | Functional ≤ 10μM |
| Z80493-2-O | SK-OV-3 (Ovarian Carcinoma Cells) (cluster #2 Of 6), Other | Other | 4900 | 0.18 | Functional ≤ 10μM |
| Z80546-1-O | TERT-RPE1 (Retinal Pigmented Epithelial Cells) (cluster #1 Of 1), Other | Other | 90 | 0.23 | Functional ≤ 10μM |
| Z80548-4-O | THP-1 (Acute Monocytic Leukemia Cells) (cluster #4 Of 5), Other | Other | 2160 | 0.19 | Functional ≤ 10μM |
| Z80559-1-O | U251 (cluster #1 Of 3), Other | Other | 500 | 0.21 | Functional ≤ 10μM |
| Z80600-2-O | XF498 (Glioma Cells) (cluster #2 Of 2), Other | Other | 3480 | 0.18 | Functional ≤ 10μM |
| Z80601-1-O | XRS6 (cluster #1 Of 1), Other | Other | 140 | 0.23 | Functional ≤ 10μM |
| Z80604-1-O | YAPC (cluster #1 Of 2), Other | Other | 1320 | 0.20 | Functional ≤ 10μM |
| Z80608-1-O | ZR-75-1 (Breast Carcinoma Cells) (cluster #1 Of 4), Other | Other | 240 | 0.22 | Functional ≤ 10μM |
| Z80682-1-O | A549 (Lung Carcinoma Cells) (cluster #1 Of 11), Other | Other | 9980 | 0.17 | Functional ≤ 10μM |
| Z80712-2-O | T47D (Breast Carcinoma Cells) (cluster #2 Of 7), Other | Other | 160 | 0.23 | Functional ≤ 10μM |
| Z80819-1-O | J774.2 (cluster #1 Of 1), Other | Other | 3667 | 0.18 | Functional ≤ 10μM |
| Z80846-1-O | F460pv8/eto Cell Line (cluster #1 Of 2), Other | Other | 740 | 0.20 | Functional ≤ 10μM |
| Z80852-1-O | A-431 (Epidermoid Carcinoma Cells) (cluster #1 Of 3), Other | Other | 591 | 0.21 | Functional ≤ 10μM |
| Z80866-1-O | GLC4 Cell Line (cluster #1 Of 1), Other | Other | 820 | 0.20 | Functional ≤ 10μM |
| Z80889-1-O | NCI-H322M (Non-small Cell Lung Carcinoma Cells) (cluster #1 Of 3), Other | Other | 1590 | 0.19 | Functional ≤ 10μM |
| Z80896-1-O | NCI-H69 (Small Cell Lung Carcinoma Cells) (cluster #1 Of 1), Other | Other | 1192 | 0.20 | Functional ≤ 10μM |
| Z80901-1-O | HaCaT (Keratinocytes) (cluster #1 Of 2), Other | Other | 550 | 0.21 | Functional ≤ 10μM |
| Z80928-1-O | HCT-116 (Colon Carcinoma Cells) (cluster #1 Of 9), Other | Other | 9500 | 0.17 | Functional ≤ 10μM |
| Z81020-3-O | HepG2 (Hepatoblastoma Cells) (cluster #3 Of 8), Other | Other | 4900 | 0.18 | Functional ≤ 10μM |
| Z81024-1-O | NCI-H460 (Non-small Cell Lung Carcinoma) (cluster #1 Of 8), Other | Other | 90 | 0.23 | Functional ≤ 10μM |
| Z81043-1-O | N592 (cluster #1 Of 2), Other | Other | 500 | 0.21 | Functional ≤ 10μM |
| Z81054-1-O | SF-268 (Glioblastoma Cells) (cluster #1 Of 3), Other | Other | 3250 | 0.18 | Functional ≤ 10μM |
| Z81065-1-O | IGROV-1 (Ovarian Adenocarcinoma Cells) (cluster #1 Of 3), Other | Other | 985 | 0.20 | Functional ≤ 10μM |
| Z81072-1-O | Jurkat (Acute Leukemic T-cells) (cluster #1 Of 10), Other | Other | 160 | 0.23 | Functional ≤ 10μM |
| Z81115-1-O | KB (Squamous Cell Carcinoma) (cluster #1 Of 6), Other | Other | 800 | 0.20 | Functional ≤ 10μM |
| Z81126-1-O | KYSE-150 Cell Line (cluster #1 Of 1), Other | Other | 700 | 0.21 | Functional ≤ 10μM |
| Z81128-1-O | KYSE-520 Cell Line (cluster #1 Of 1), Other | Other | 410 | 0.21 | Functional ≤ 10μM |
| Z81130-1-O | KYSE-70 Cell Line (cluster #1 Of 1), Other | Other | 790 | 0.20 | Functional ≤ 10μM |
| Z81160-1-O | Lewis Lung Carcinoma Cell Line (cluster #1 Of 1), Other | Other | 180 | 0.22 | Functional ≤ 10μM |
| Z81244-1-O | J774 (Macrophage Cells) (cluster #1 Of 1), Other | Other | 577 | 0.21 | Functional ≤ 10μM |
| Z81247-1-O | HeLa (Cervical Adenocarcinoma Cells) (cluster #1 Of 9), Other | Other | 8930 | 0.17 | Functional ≤ 10μM |
| Z81252-3-O | MDA-MB-231 (Breast Adenocarcinoma Cells) (cluster #3 Of 11), Other | Other | 700 | 0.21 | Functional ≤ 10μM |
| Z81280-1-O | NCI-H226 (Non-small Cell Lung Carcinoma Cells) (cluster #1 Of 3), Other | Other | 240 | 0.22 | Functional ≤ 10μM |
| Z81284-1-O | NCI-H647 (cluster #1 Of 2), Other | Other | 80 | 0.24 | Functional ≤ 10μM |
| Z81335-2-O | HCT-15 (Colon Adenocarcinoma Cells) (cluster #2 Of 5), Other | Other | 900 | 0.20 | Functional ≤ 10μM |
| Z80156-1-O | HL-60 (Promyeloblast Leukemia Cells) (cluster #1 Of 4), Other | Other | 300 | 0.22 | ADME/T ≤ 10μM |
| Z80291-1-O | MRC5 (Embryonic Lung Fibroblast Cells) (cluster #1 Of 3), Other | Other | 3930 | 0.18 | ADME/T ≤ 10μM |
| Uniprot | Swissprot | Description | Affinity (nM) | LE (kcal/mol/atom) | Type |
|---|---|---|---|---|---|
| CASP3_HUMAN | P42574 | Caspase-3, Human | 1000 | 0.20 | Binding ≤ 1μM |
| TOP2A_HUMAN | P11388 | DNA Topoisomerase II Alpha, Human | 810 | 0.20 | Binding ≤ 1μM |
| TOP2B_HUMAN | Q02880 | DNA Topoisomerase II Beta, Human | 810 | 0.20 | Binding ≤ 1μM |
| CASP3_HUMAN | P42574 | Caspase-3, Human | 1000 | 0.20 | Binding ≤ 10μM |
| TOP2A_HUMAN | P11388 | DNA Topoisomerase II Alpha, Human | 810 | 0.20 | Binding ≤ 10μM |
| TOP2B_HUMAN | Q02880 | DNA Topoisomerase II Beta, Human | 810 | 0.20 | Binding ≤ 10μM |
| Z80008 | Z80008 | 5637 (Epithelial Bladder Carcinoma Cells) | 530 | 0.21 | Functional ≤ 10μM |
| Z80852 | Z80852 | A-431 (Epidermoid Carcinoma Cells) | 591 | 0.21 | Functional ≤ 10μM |
| Z103203 | Z103203 | A375 | 3920 | 0.18 | Functional ≤ 10μM |
| Z103204 | Z103204 | A427 | 130 | 0.23 | Functional ≤ 10μM |
| Z80682 | Z80682 | A549 (Lung Carcinoma Cells) | 1060 | 0.20 | Functional ≤ 10μM |
| Z80025 | Z80025 | ACHN (Renal Adenocarcinoma Cells) | 2150 | 0.19 | Functional ≤ 10μM |
| Z80026 | Z80026 | AGS (Gastric Adenocarcinoma Cells) | 360 | 0.21 | Functional ≤ 10μM |
| Z80035 | Z80035 | B16 (Melanoma Cells) | 130 | 0.23 | Functional ≤ 10μM |
| Z80064 | Z80064 | CCRF-CEM (T-cell Leukemia) | 2 | 0.29 | Functional ≤ 10μM |
| Z80068 | Z80068 | CCRF-SB (Lymphoblastic Leukemia Cells) | 100 | 0.23 | Functional ≤ 10μM |
| Z80088 | Z80088 | CHO (Ovarian Cells) | 350 | 0.22 | Functional ≤ 10μM |
| Z100733 | Z100733 | CT26 (Colon Carcinoma Cells) | 200 | 0.22 | Functional ≤ 10μM |
| Z80112 | Z80112 | DAN-G | 380 | 0.21 | Functional ≤ 10μM |
| TOP1_HUMAN | P11387 | DNA Topoisomerase I, Human | 160 | 0.23 | Functional ≤ 10μM |
| TOP1_MOUSE | Q04750 | DNA Topoisomerase I, Mouse | 180 | 0.22 | Functional ≤ 10μM |
| TOP2A_MOUSE | Q01320 | DNA Topoisomerase II Alpha, Mouse | 180 | 0.22 | Functional ≤ 10μM |
| TOP2A_HUMAN | P11388 | DNA Topoisomerase II Alpha, Human | 160 | 0.23 | Functional ≤ 10μM |
| TOP2B_MOUSE | Q64511 | DNA Topoisomerase II Beta, Mouse | 180 | 0.22 | Functional ≤ 10μM |
| TOP2B_HUMAN | Q02880 | DNA Topoisomerase II Beta, Human | 160 | 0.23 | Functional ≤ 10μM |
| Z80125 | Z80125 | DU-145 (Prostate Carcinoma) | 1300 | 0.20 | Functional ≤ 10μM |
| Z80846 | Z80846 | F460pv8/eto Cell Line | 740 | 0.20 | Functional ≤ 10μM |
| Z80866 | Z80866 | GLC4 Cell Line | 4000 | 0.18 | Functional ≤ 10μM |
| Z80901 | Z80901 | HaCaT (Keratinocytes) | 550 | 0.21 | Functional ≤ 10μM |
| Z80928 | Z80928 | HCT-116 (Colon Carcinoma Cells) | 1700 | 0.19 | Functional ≤ 10μM |
| Z81335 | Z81335 | HCT-15 (Colon Adenocarcinoma Cells) | 1090 | 0.20 | Functional ≤ 10μM |
| Z81247 | Z81247 | HeLa (Cervical Adenocarcinoma Cells) | 1290 | 0.20 | Functional ≤ 10μM |
| Z81020 | Z81020 | HepG2 (Hepatoblastoma Cells) | 4100 | 0.18 | Functional ≤ 10μM |
| Z80156 | Z80156 | HL-60 (Promyeloblast Leukemia Cells) | 0.1 | 0.33 | Functional ≤ 10μM |
| Z50587 | Z50587 | Homo Sapiens | 990 | 0.20 | Functional ≤ 10μM |
| Z80164 | Z80164 | HT-1080 (Fibrosarcoma Cells) | 250 | 0.22 | Functional ≤ 10μM |
| Z80166 | Z80166 | HT-29 (Colon Adenocarcinoma Cells) | 10000 | 0.17 | Functional ≤ 10μM |
| Z81065 | Z81065 | IGROV-1 (Ovarian Adenocarcinoma Cells) | 984.5 | 0.20 | Functional ≤ 10μM |
| Z81244 | Z81244 | J774 (Macrophage Cells) | 576.7 | 0.21 | Functional ≤ 10μM |
| Z80819 | Z80819 | J774.2 | 2133.3 | 0.19 | Functional ≤ 10μM |
| Z80179 | Z80179 | J82 (Bladder Carcinoma Cells) | 2500 | 0.19 | Functional ≤ 10μM |
| Z81072 | Z81072 | Jurkat (Acute Leukemic T-cells) | 1200 | 0.20 | Functional ≤ 10μM |
| Z80186 | Z80186 | K562 (Erythroleukemia Cells) | 1210 | 0.20 | Functional ≤ 10μM |
| Z81115 | Z81115 | KB (Squamous Cell Carcinoma) | 10000 | 0.17 | Functional ≤ 10μM |
| Z80188 | Z80188 | KB 3-1 (Cervical Epithelial Carcinoma Cells) | 566.5 | 0.21 | Functional ≤ 10μM |
| Z81126 | Z81126 | KYSE-150 Cell Line | 700 | 0.21 | Functional ≤ 10μM |
| Z81128 | Z81128 | KYSE-520 Cell Line | 410 | 0.21 | Functional ≤ 10μM |
| Z81130 | Z81130 | KYSE-70 Cell Line | 790 | 0.20 | Functional ≤ 10μM |
| Z80193 | Z80193 | L1210 (Lymphocytic Leukemia Cells) | 200 | 0.22 | Functional ≤ 10μM |
| Z81160 | Z81160 | Lewis Lung Carcinoma Cell Line | 1100 | 0.20 | Functional ≤ 10μM |
| Z80211 | Z80211 | LoVo (Colon Adenocarcinoma Cells) | 2300 | 0.19 | Functional ≤ 10μM |
| Z80224 | Z80224 | MCF7 (Breast Carcinoma Cells) | 1000 | 0.20 | Functional ≤ 10μM |
| Z81252 | Z81252 | MDA-MB-231 (Breast Adenocarcinoma Cells) | 1230 | 0.20 | Functional ≤ 10μM |
| Z80244 | Z80244 | MDA-MB-468 (Breast Adenocarcinoma) | 600 | 0.21 | Functional ≤ 10μM |
| Z80284 | Z80284 | MOLT-3 (T-lymphoblastic Leukemia Cells) | 65 | 0.24 | Functional ≤ 10μM |
| Z80285 | Z80285 | MOLT-4 (Acute T-lymphoblastic Leukemia Cells) | 0.1 | 0.33 | Functional ≤ 10μM |
| Z80288 | Z80288 | MOVP-3 | 7550 | 0.17 | Functional ≤ 10μM |
| Z80295 | Z80295 | MT4 (Lymphocytes) | 1250 | 0.20 | Functional ≤ 10μM |
| Z81043 | Z81043 | N592 | 500 | 0.21 | Functional ≤ 10μM |
| Z81280 | Z81280 | NCI-H226 (Non-small Cell Lung Carcinoma Cells) | 240 | 0.22 | Functional ≤ 10μM |
| Z80889 | Z80889 | NCI-H322M (Non-small Cell Lung Carcinoma Cells) | 1590 | 0.19 | Functional ≤ 10μM |
| Z80322 | Z80322 | NCI-H358 (Lung Carcinama Cells) | 1500 | 0.19 | Functional ≤ 10μM |
| Z81024 | Z81024 | NCI-H460 (Non-small Cell Lung Carcinoma) | 100 | 0.23 | Functional ≤ 10μM |
| Z81284 | Z81284 | NCI-H647 | 80 | 0.24 | Functional ≤ 10μM |
| Z80896 | Z80896 | NCI-H69 (Small Cell Lung Carcinoma Cells) | 1192.2 | 0.20 | Functional ≤ 10μM |
| Z80362 | Z80362 | P388 (Lymphoma Cells) | 100 | 0.23 | Functional ≤ 10μM |
| Z80390 | Z80390 | PC-3 (Prostate Carcinoma Cells) | 1700 | 0.19 | Functional ≤ 10μM |
| Z50425 | Z50425 | Plasmodium Falciparum | 3981.07171 | 0.18 | Functional ≤ 10μM |
| Z100752 | Z100752 | Renca (Renal Carcinoma Cells) | 2900 | 0.18 | Functional ≤ 10μM |
| Z80435 | Z80435 | RT-112 | 220 | 0.22 | Functional ≤ 10μM |
| Z80436 | Z80436 | RT-4 | 1330 | 0.20 | Functional ≤ 10μM |
| Z81054 | Z81054 | SF-268 (Glioblastoma Cells) | 3250 | 0.18 | Functional ≤ 10μM |
| Z80473 | Z80473 | SISO | 150 | 0.23 | Functional ≤ 10μM |
| Z80475 | Z80475 | SK-BR-3 (Breast Adenocarcinoma) | 300 | 0.22 | Functional ≤ 10μM |
| Z80482 | Z80482 | SK-MEL-2 (Melanoma Cells) | 1170 | 0.20 | Functional ≤ 10μM |
| Z80485 | Z80485 | SK-MEL-28 (Melanoma Cells) | 850 | 0.20 | Functional ≤ 10μM |
| Z80490 | Z80490 | SK-MES-1 | 2500 | 0.19 | Functional ≤ 10μM |
| Z80491 | Z80491 | SK-N-MC (Neuroepithelioma Cells) | 275 | 0.22 | Functional ≤ 10μM |
| Z80493 | Z80493 | SK-OV-3 (Ovarian Carcinoma Cells) | 1720 | 0.19 | Functional ≤ 10μM |
| Z103413 | Z103413 | SW948 | 1300 | 0.20 | Functional ≤ 10μM |
| Z80712 | Z80712 | T47D (Breast Carcinoma Cells) | 100 | 0.23 | Functional ≤ 10μM |
| Z80546 | Z80546 | TERT-RPE1 (Retinal Pigmented Epithelial Cells) | 90 | 0.23 | Functional ≤ 10μM |
| Z80548 | Z80548 | THP-1 (Acute Monocytic Leukemia Cells) | 1830 | 0.19 | Functional ≤ 10μM |
| Z80559 | Z80559 | U251 | 500 | 0.21 | Functional ≤ 10μM |
| Z80600 | Z80600 | XF498 (Glioma Cells) | 1720 | 0.19 | Functional ≤ 10μM |
| Z80601 | Z80601 | XRS6 | 140 | 0.23 | Functional ≤ 10μM |
| Z80604 | Z80604 | YAPC | 1320 | 0.20 | Functional ≤ 10μM |
| Z80608 | Z80608 | ZR-75-1 (Breast Carcinoma Cells) | 240 | 0.22 | Functional ≤ 10μM |
| Z80156 | Z80156 | HL-60 (Promyeloblast Leukemia Cells) | 300 | 0.22 | ADME/T ≤ 10μM |
| Z80291 | Z80291 | MRC5 (Embryonic Lung Fibroblast Cells) | 3900 | 0.18 | ADME/T ≤ 10μM |
| Description | Species |
|---|---|
| Activation of caspases through apoptosome-mediated cleavage | |
| Activation of DNA fragmentation factor | |
| Apoptotic cleavage of cell adhesion proteins | |
| Apoptotic cleavage of cellular proteins | |
| Caspase-mediated cleavage of cytoskeletal proteins | |
| Degradation of the extracellular matrix | |
| G0 and Early G1 | |
| NADE modulates death signalling | |
| Role of DCC in regulating apoptosis | |
| Signaling by Hippo | |
| SMAC binds to IAPs | |
| SMAC-mediated dissociation of IAP:caspase complexes | |
| Stimulation of the cell death response by PAK-2p34 |
